MEIRAGTX HOLDINGS PLC

(MGTX)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
8.710 USD   +7.66%
05/13Chardan Lowers MeiraGTx Holdings's Price Target to $46 From $55, Maintains Buy Rating
MT
05/13Barclays Lowers MeiraGTx Holdings's Price Target to $18 From $32, Maintains Overweight Rating
MT
05/13Piper Sandler Adjusts MeiraGTx Holdings' Price Target to $30 From $40, Reiterates Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MeiraGTx Gets $30 Million Milestone Payment From Janssen Pharmaceuticals

01/27/2022 | 08:53am EDT

By Chris Wack


MeiraGTx Holdings PLC said it received a $30 million payment from Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Cos. of Johnson & Johnson, for a clinical milestone in a Phase 3 trial of botaretigene sparoparvovec.

Botaretigene sparoparvovec is an investigational gene therapy for the treatment of X-linked retinitis pigmentosa. The Phase 3 Lumeos trial is a global study of botaretigene sparoparvovec which is now dosing participants.

MeiraGTx and Janssen are jointly developing botaretigene sparoparvovec as part of a broader collaboration to develop and commercialize gene therapies for the treatment of inherited retinal diseases.

MeiraGTx remains eligible to receive additional development and commercial milestones for botaretigene sparoparvovec as well as for other programs as part of the collaboration agreement.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

01-27-22 0853ET

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 1.75% 176.98 Delayed Quote.1.68%
MEIRAGTX HOLDINGS PLC 7.66% 8.71 Delayed Quote.-63.31%
All news about MEIRAGTX HOLDINGS PLC
05/13Chardan Lowers MeiraGTx Holdings's Price Target to $46 From $55, Maintains Buy Rating
MT
05/13Barclays Lowers MeiraGTx Holdings's Price Target to $18 From $32, Maintains Overweight ..
MT
05/13Piper Sandler Adjusts MeiraGTx Holdings' Price Target to $30 From $40, Reiterates Overw..
MT
05/12MEIRAGTX HOLDINGS PLC Management's Discussion and Analysis of Financial Condition and ..
AQ
05/12MeiraGTx Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
05/12MeiraGTx Reports First Quarter 2022 Financial and Operational Results
GL
05/10TRANSCRIPT : MeiraGTx Holdings plc Presents at Bank of America 2022 Healthcare Conference,..
CI
05/04MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Li..
GL
05/04MeiraGTx Holdings plc Presents Clinical Data on Botaretigene Sparoparvovec for Treatmen..
CI
04/27MEIRAGTX : Appoints Debra Yu, MD to Board of Directors - Form 8-K
PU
More news
Analyst Recommendations on MEIRAGTX HOLDINGS PLC
More recommendations
Financials (USD)
Sales 2022 34,4 M - -
Net income 2022 -103 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,72x
Yield 2022 -
Capitalization 389 M 389 M -
Capi. / Sales 2022 11,3x
Capi. / Sales 2023 8,48x
Nbr of Employees 315
Free-Float 71,9%
Chart MEIRAGTX HOLDINGS PLC
Duration : Period :
MeiraGTx Holdings plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEIRAGTX HOLDINGS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 8,71 $
Average target price 30,57 $
Spread / Average Target 251%
EPS Revisions
Managers and Directors
Alexandria Forbes President, Chief Executive Officer & Director
Richard Giroux Chief Operating & Financial Officer
Keith Reginald Harris Director
Robert K. Zeldin Chief Medical Officer
Ellen Hukkelhoven Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MEIRAGTX HOLDINGS PLC-63.31%389
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612